Immix Biopharma (IMMX) Accounts Payables (2020 - 2026)

Immix Biopharma has disclosed Accounts Payables across 7 years of filings, most recently posting $193715.0 for Q1 2026.

• Accounts Payables for Q1 2026 came in at $193715.0, up 52.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $193715.0 (up 52.09% YoY), and the FY2025 annual result was $5.4 million, up 4100.71% from the prior year.
• Accounts Payables came in at $193715.0 for Q1 2026 at Immix Biopharma, down from $5.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $6.6 million in Q2 2025 to a low of $122594.0 in Q1 2024.
• The 5-year median for Accounts Payables is $1.3 million (2022), against an average of $2.2 million.
• Peak annual rise in Accounts Payables reached 4100.71% in 2025, while the deepest fall reached 97.37% in 2025.
• Immix Biopharma's Accounts Payables stood at $1.3 million in 2022, then soared by 192.3% to $3.7 million in 2023, then sank by 96.52% to $129567.0 in 2024, then jumped by 4100.71% to $5.4 million in 2025, then plunged by 96.44% to $193715.0 in 2026.
• The last three Accounts Payables figures came in at $193715.0 (Q1 2026), $5.4 million (Q4 2025), and $170896.0 (Q3 2025), per Business Quant data.